Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Biotech
ESMO: Daiichi, Merck move ovarian cancer ADC toward pivotal test
The partners saw a 50.5% response rate in a study that informed the selection of their phase 3 dose.
Nick Paul Taylor
Oct 20, 2025 10:45am
ESMO: Tubulis' next-gen ADC lives up to hype with 59% ORR
Oct 19, 2025 4:15am
Genmab discards ADC from $1.8B ProfoundBio buy
Sep 16, 2025 10:33am
PMV plots ovarian cancer filing after seeing midphase data
Sep 10, 2025 9:40am
Zymeworks drops clinical-stage TCE over benefit-risk profile
Sep 2, 2025 8:10am
Nuvectis axes ovarian cancer program after seeing phase 1b data
Jul 31, 2025 9:15am
